INTRODUCTION
In 1982, Arnold Pick described cases of cognitive deterioration, notably in the language, associated with focal brain atrophy or circumscribed to the temporal and frontal lobes. He therefore challenged the existing dogma at that time, in which the process of brain degeneration would be invariably diffuse. 1 In 1911, Dr. Alois Alzheimer (1864-1915) described the histopathological status related to these patients, pointing the absence of senile plaques and neurofibrillary tangles, and the presence of neuronal inclusions (later called "Pick bodies") and swollen cells (later called "Pick cells"). 1 However, during the 20 th century, these patients with frontotemporal lobar degeneration were generically referred to as patients with dementia, being often diagnosed with Alzheimer disease (AD). 2 In 1994, two major research groups from Lund, Sweden, and Manchester, England proposed clinical and neuropathological criteria for the diagnosis of frontotemporal dementia (FTD). 3 With regard to the neuropathological criteria, it has been recognized that only part of the individuals with FTD (25%) show the typical findings of Pick bodies and cells according to the original description. The most commonly observed pattern is the microvacuolar (60%), characterized by neuronal loss and microvacuolar degeneration. For the rest of the patients (15%),
there is a concomitance of pathological findings of microvacuolar degeneration and motor neuron disease. 2, 3 In clinical terms, it has been suggested that, besides FTD, the status of semantic dementia and nonfluent progressive aphasia would be clinical manifestations of the frontotemporal lobar degeneration. 4 The establishment of the criteria for the diagnosis of FTD services found values similar to those obtained in this community study, identifying the FTD as the second main cause of degenerative dementia. 6 Since the behavioral symptoms are very prominent in FTD, these patients are often initially assessed by psychiatrists, who must recognize this clinical entity. Therefore, the aim of the following study is to discuss the clinical characteristics of FTD, as well as the perspectives of the pharmacological therapy. In order to do so, we surveyed the literature related to FTD, initially based on review articles over the past 5 years at MEDLINE database, and later original articles cited in these references, whenever they were considered relevant for our objective.
Clinical characteristics of FTD
FTD is mainly manifested in the presenium, between 45 and 65 years of age, and it occurs in the same proportion in men and women. The family history of dementia is seen in half of cases, which suggests a major role of genetic factors in the development of FTD. 2, 7 FTD is characterized by a significant change in personality and behavior, with relative preservation of the cognitive functions praxis, gnosia and memory 3, 4 (table 1) . Visuospatial skills are also intact. Language in its turn is progressively affected, and there might be difficulties in the understanding and verbal expression, with reduction in fluency or even mutism. The FTD diagnosis is not made or there is a late diagnosis, once memory is preserved at the disease onset, and the change of this function is requested by the syndromic diagnosis of dementia, according to the criteria of the Diagnostic and Statistical Manual of Mental Disorders (DSM-IV), 8 which give too much emphasis on cognitive deficits. 9,10 The psychiatrist plays a major role in the early recognition of FTD, because the behavioral and personality changes are very significant. The complaints are often brought about by family members, since most patients ignore their changes in personality, behavior and social conduct. Therefore, the development of these symptoms in the presenium should be a warning for the diagnosis of FTD. 
V. Relative diagnostic exclusion features (common to other frontotemporal lobar degeneration syndromes):
A. Chronic alcoholism;
B. Sustained hypertension;
C. History of vascular disease (e.g., angina, claudication).
The functional division of the frontal lobe into three distinct areas -orbital, medial and dorsolateral -, which constitute parallel and segregated circuits with subcortical structures, allows an explanatory approach of the FTD symptoms. [11] [12] [13] In this sense, the orbital lesion would be associated with disinhibition, impulsiveness and antisocial and stereotyped behaviors. Stereotyped or ritualistic behaviors may take different forms, from simple motor and verbal stereotypes, such as repeating gestures and words frequently, to complex routines, which include changes in eating habits, with an increase in oral ingestion and preference for sweet foods. 3, 4 The frontomedial lesion is correlated with apathy, passiveness, loss of motivation and tendency to social isolation.
Depressive symptoms might be present. As there is a progression of the degenerative process to the Neuroimage examinations tend to show atrophy of frontotemporal lobes. However, in the early stages of FTD, such structural changes may not be evident. 15 In these cases, the single photon emission computed tomography (SPECT) may reveal hypoperfusion in frontal areas (mainly ventromedial) and/or temporal (mainly anterolateral). It is a more sensitive examination to help in the diagnosis of FTD. 16 As previously said, besides FTD, which represents more than 70% of cases, two other clinical conditions are manifestations of frontotemporal lobar degeneration. 4 The first one is the semantic dementia, also called temporal variant of FTD, responsible for around 15% of cases.
Patients with semantic dementia present a progressive degeneration of verbal comprehension and of the recognition of objects and people (agnosia), with great difficulty to name them. Nonetheless, the grammatical and phonological structure of patients' discourse remains intact. Behavioral changes tend to be less prominent than in FTD. 4, 10 The other manifestation of the frontotemporal lobar 8 degeneration is the nonfluent progressive aphasia, marked by a progressive reduction in verbal fluency, discourse with phonological and syntactic errors and anomia. 4, 17 In this case, the behavioral changes are also less intense.
The main differential diagnosis of FTD is with AD, which is responsible for more than half of dementia cases. Patients with AD seek for medical help complaining of memory changes, visuospatial functions or other cognitive functions. 18 The behavioral and/or personality changes occur later. In patients with FTD, the behavioral changes take place early, whereas cognitive functions are relatively preserved in the early stages of the disease.
The differential diagnosis with VD, which may also affect frontotemporal structures, is On the neuropsychological evaluation of patients with mild FTD, there was impairment only in gambling tasks and reversal learning tasks. 19 These patients presented a normal performance in an extensive battery of memory and executive function tests, such as recognition memory, work memory, planning and control of the focus of attention. 19 In a comparative study of patient s with FTD, semantic dementia and AD involving language tests, patients with semantic dementia had a worse performance than those with FTD in the Boston naming test and in the verbal fluency test.
Patients with FTD were worse than those with AD only in the verbal fluency test. 20 Therefore, we conclude that several neuropsychological screening tests, which are originally developed to screen the cognitive deficits present in AD, especially memory, fail to identify the FTD. 10 On the other hand, tests like the gambling test, reversal learning and language tasks might be useful in the differential diagnosis of FTD. 20 Interestingly, in gambling tests, patients with FTD showed an intact ability for probabilistic judgements, but adopted an excessive risk behavior when making decisions. However, it is not about inhibitory lack of inhibitory control and premature responses, since patients take more time than controls thinking about their decisions. This risk behavior may be related to the lack of insight about the consequences of the behavior itself, and thus be associated with sociopathic tendencies seen in FTD. 19, 21 Individuals with different orbitofrontal structural lesions also present a disadvantageous performance in gambling tasks. 22 Patients with FTD in their turn showed a perseverative behavior in the reversal learning task, in which previously reinforced stimuli became neutral, i.e., they maintained the standard of responses according to the previous learning. 19 Individuals with brain injuries affecting the orbitofrontal cortex also show impairment in reversal learning tasks. 23 Together, these studies suggest that assessment tests of orbitofrontal functions are quite sensitive in the FTD identification.
Specific neuropsychiatric inventories to identify FTD have also been developed, with a focus on behavioral changes, such as the Neuropsychiatric Inventory and the Frontal Behavioral
Inventory. 25 
Pharmacological therapy of FTD
The current therapeutic approach of neurodegenerative diseases is essentially based on the strategy of neurotransmitter replacement. 18, 26 As opposed to what occurs in other primary dementias, such as in AD and in dementia with Lewy bodies, neurochemical studies did not show changes in the cholinergic system in FTD. 27 Therefore, the acetylcholinesterase inhibitors used in the treatment of these primary dementias did not benefit patients with FTD. 2, 28, 29 Changes in the serotoninergic system are found in different clinical conditions that manifest apathy/depression or disinhibition/impulsiveness. 30 Serotoninergic deficits were also found in patients with FTD, in which these behavioral disorders are striking. 31 It is interesting to note that studies on the serotoninergic modulation of the prefrontal cortex function indicate that this neurotransmitter affects the tasks related to the orbitofrontal part selectively, such as the gambling task and the reversal learning task, which are also those in which patients with FTD showed a most significant impairment. 21, 32 A series of open studies showed therapeutic efficacy of serotoninergic drugs, remarkably the selective serotonin reuptake inhibitors, to control the behavioral symptoms of FTD. 28, 29, 33 Nonetheless, Deakin et al. 34 did not verify any benefit of a selective serotonin reuptake inhibitor, the paroxetine, in doses up to 40 mg/day, in a double-blind placebo-controlled study involving 10 patients with FTD. Although such discrepancy may be due to methodological reasons, it is important to highlight that, in the study by Deakin et al., 34 the paroxetine was used for only 6 weeks, whereas in the open studies it was used for more than 3 months. This is a major issue, since it was demonstrated that the selective serotonin reuptake inhibitors affect the serotoninergic function in the orbital prefrontal cortex after 8 weeks of use, but not after 3 weeks. 35 Therefore, several weeks of training may be needed before achieving the desired therapeutic effect in FTD, as well as in the obsessive-compulsive disorder, which is a condition that also involves serotoninergic and orbital prefrontal cortex disorder. That is why other controlled clinical tests must be performed to evaluate the real efficacy of serotoninergic drugs to control the behavioral symptoms of FTD.
The role of the dopaminergic dysfunction in FTD is controversial, once there are both positive 36 and negative results. 27 Behavioral disorders, particularly disinhibition and aggressiveness, that expose the patient or their caretakers to risks, may be controlled with dopaminergic antagonists or antipsychotic drugs. 28, 29 In this case, the current tendency is to preferentially use the atypical antipsychotic drugs. 29 It has been proposed that even the dopaminergic agonists, such as the bromocriptine, may improve certain dimensions of the frontal cognitive functioning. 28 However, it is stressed that the dopamine is related, above all, to the modulation of executive functions, such as work memory, planning and attention control, and to the dorsolateral aspect of the prefrontal cortex, which are less implicated in FTD, but may be affected later in the disease progression. 32 More systematic studies are thus needed to confirm the therapeutic benefit of dopaminergic drugs in FTD.
In terms of therapeutic approach specifically oriented to the pathophysiological process subjacent to the FTD, interventions that inhibit the aggregation of the tau protein may be promising in the future. It is important to highlight that the pathological aggregation of the tau protein seems to be related to the pathogenesis of several neurodegenerative diseases, generically called taupathies, which include AD, FTD, corticobasal degeneration and progressive supranuclear palsy. 
CONCLUSION
In the FTD, there is a striking change in the patient's behavior and personality, with relative preservation of the cognitive functions traditionally assessed for the diagnosis of dementia, particularly the memory. Psychiatrists thus play a major role in the recognition of this type of
